Tuberculosis ד"ר מנדל גלזר מנהל מכון רוקח ומלש"ח ירושלים...
-
Upload
trinity-eades -
Category
Documents
-
view
274 -
download
3
Transcript of Tuberculosis ד"ר מנדל גלזר מנהל מכון רוקח ומלש"ח ירושלים...
Tuberculosis
ד"ר מנדל גלזר
מנהל מכון רוקח ומלש"ח ירושלים
שירותי בריאות כללית, מחוז ירושלים
מסונף לאוניברסיטה העברית
מכון הריאה ב"ח הדסה ע"כ
מלש"ח – מרכז לאבחון וטיפול בשחפת
•9 " בארץ חים מלשהאזוריות • הבריאות לשכותרוקח – • מרכז ירושלים
מרכז רפואי על שם ד"ר י.ל. רוקח
מלש"ח
מרפאות קהילה
מלש"חים אחרים
לשכת הבריאות
משרד הבריאות
צה"ל
מבוטחי כלעובדים זריםהקופות
מרכז קליטה
בתי חוליםכלליים
בי"חספציפיים
History Terms
• Consumption• Phthisis [ Greek ]• Phthisis Pulmonalis• Scropula• Tabes Mesenterica• Koch’s Disease
TB History
• 1020 – Ibn Sina [ Avicena ] described in first as contagious disease
• 1839 - Senabsin - name Tuberculosis • 1859 – First sanatorium in Germany • 1882 – R.Koch found bacilli • 1905 – Nobel Price
1906 – A. Galmette and Camele Gurien – first immunisation
TB History
• 1907 – National TB Association founded in US and Canada
• 1921 – First human vaccination used in France
• 1946 – Streptomycin was developed • 80’s – Drug resistance appeared • The 20th _ TB kill’s more than 100 million
people
Incidence
- 8,8 million new cases and 1,4 million
died in 2010.- 19-43% of the world`s population are
infected by M.Tuberculosis.- >95% of cases occur in developing
countries.
TB - USA
Tuberculosis
. Infectious disease caused by Mycobacterium Tuberculosis
• Transmitted from a person with active lung disease
• Airborne transmission• Exposure time, host susceptibility dependant
MT COMPLEX
. Mycobacterium Tuberculosis• Mycobacterium Bovis• Mycobacterium Africanum• M.Microti, M.Pinnipedii, M.Carpae
MTB• Small rod-like bacillus• Aerobic• Divides every 16-20 hours• Can identify under regular microscopy• Ziehl-Neelsen stain• Fluorescent microscopy• Rhodamine, Ahramine stain
Mycobacterium TB
Sputum ZN Stained
TB
Tuberculosis
• Active Disease• Latent [ LTI ]
Tuberculosis
• MDR [ Multi drug resistance ]- Rifampicin, Isoniazid
• XDR [ Extensive drug resistance ] – Rif., Ison., Fluoroqinolones, Aminoglicosides
• HIV
Lung TB
TB Diagnostics
• Sputum • Bronchoscopes• Gastric Aspiration• Histopathology [ Biopsy ]
Rapid TB Tests
• NAA [ Nucleic Acid Amplification ]• Gen-Probe MTD• Enhanced MTD• Amplicor MT Test
TB in Children
• Under 5year triad of close contact, positive TST, suggestive findings on the x-ray [ primary complex, opacification with hilar or subcarinal lymphadenopathy ] or physical examination are useful for diagnosis for active TB
• Gastric aspiration
Relative Risk for TB
• AIDS 110- 170• HIV 50 - 110• Transplant 20 - 74• CA Head/Neck 16• TNF Inhibitor 1,7 – 9• Solitary Granuloma 2• Apical Fibronodules 6 - 19• Resent TB Inf [ under 2 years ] 15
Relative Risk for TB
• CRF – Hemodialysis 10-25• Silicosis 30• Anti – TNF 1,7 - 9 • Young age [under 5 ] 2,2 - 5• Glucocorticoids 4,9• DM all types 2 – 3,6• Smoker 1 p/d 2 – 3• Underweight [ 85% ] 2 - 3
Close Contact - Disease Risk
• Under 1 year old 50%• 1 - 2 years 12% – 25%• 2 – 5 years 5%• 5 – 10 years 2%• Adolescent , young adults 10% - 20%• Other adults 3% - 5%
LTI Diagnosis
• TST• Interferon-Gamma release assay [IGRA ]: Enzyme-linked immunosorbent assay -
Quantiferon e.g. Elisa Enzyme-linked immunospot assay – Elipsot
e.g. T-Spot TB assay.
Tuberculin test (Mantoux)
• Intradermal injection of 5 TU (tuberculin units) of purified protein derivative (PPD).
• Induration measured after 48-72 hours.• Booster [ two step testing ]• Conversion: an increase of 6-10mm to
>10mm.
Booster Response, Conversion
• Booster – 10mm or more and has increased by 6mm since the previous in the absence of exposure. Lover risk than initial positive TST
• Conversion – 10mm or more and has increased by 6mm since the previous up to 8weks after initial negative TST in the setting of recent exposure
• Reaction 10 and more mm should be referred for medical evaluation to exclude active TB
אצל ילידי ישראלPPDהתפלגות תוצאות
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
לא ידוע+00-55-1010-1515
2008 2009 2010
Close Contact
• PPD Negative – Second test should undergo 8 – 12 weeks later
Potential causes of false negative Tuberculin test : Technical - correctible
Tuberculin material : improper storage [ exposure to light, heat ], contamination, improper dilution, chemical denaturation
Administration: injection of too little tuberculin, or too deeply, or more than 20 minutes after drawing up into the syringe
Reading: inexperienced or biased reader, error in recording
Infections: Active TB [ especially if advanced ], bacterial infections [ typhoid fever, brucellosis, typhus, leprosy, pertussis ]. HIV inf[ especially if CD count less than 200 ], viral infection [ measles,
mumps, varicella ], fungal infection [ blastomycosis ]
Live virus vaccination : measles, mumps, polio Immunosuppressive drugs : corticosteroids, TNF inhibit, others Metabolic disease: CRF, severe malnutrition, stress [ surgery, burns ]
Diseases of lymphoid organs: Lymphoma, CLL, Sarcoidosis
Age under 6 months, elderly
Potential causes of false negative tuberculin tests: Biologic – not correctible
LTI Diagnosis
IGRAs Specificity 95%, Sensitivity 80-90% TST - Specificity 97% in non BCG, and 60% in
BCG administered, Sensitivity -80%IGRAs sensitivity is diminished in HIV with lower
CD4 [ TSPOT is less affected ]M.Kansasii, M.Marinum affect
LTI Diagnosis
USA – IGRAs used, but not in addition to TSTCanada – IGRAs is appropriated in the setting of
negative TSTUK – TST is the first-line test. If positive – may be
considered IGRA depending of BCG status
TB - TREATMENT
• DOT [ Direct Observed Therapy ]
TB Treatment
• First Line [ INH, RIF, ETH, PZM, Rifabutin]• Second Line [ Cycloserine, Ethionamide,
Streptomycin, Amikacin, Kanamycin, Capreomycin, PAS, Levofloxacin, Moxyfloxcin ]
• New drugs [ Interferon, Linezolid ] • Surgery
Active TB - Treatment
Prolonged Treatment in cavitary , miliary TB
In pericarditis, meningitis – corticosteroids
Treatment failure – positive sputum culture after 4months treatment - continue 4 drug regimen
Treatment Regimes for LTBI
Isoniazid 6 to 9 months.
Rifampicin 4 months; children 6 months.
Rifampicin + Isoniazid 3 months.
Liver and kidney functions monitoring.
Risk of Isoniazid-Induced Hepatitis
• More than 65 years - more than 5%
• 50 – 65 years - 3-5%
• Less 50 years – less than 3%
• Less than 35years – less than 1%
BCG
Benefits: diminished risk of TB meningitis
Reaction 3-19mm in the first 3 months, after less than 10mm
Should not be administrated in individuals with immune compromise
BCG
לילודים ולילדים ממשפחות עולים חדשים •ותושבים שאינם אזרחי ישראל המגיעים
גבוהTBמארצות בהן שכיחות [ שלא חוסן או שאין 4מייד אחרי לידה ועד גיל •
נשלל ]HIVעדות על החיסון וכש
BCG Adverse Events - 5%• Fever - 2,9%• Signif. Proteinurua - 1%• Granulomatous Prostatitis - 0,9%• Pneumonitis - 0,7%• Granulomatous Hepatitis - 0,7%• Artralgia - 0,5%• Epididymitis - 0,4%• Cystitis
BCG – Adverse Events
• Sepsis - 0,4%• Rash - 0,3%• Uretral Obstruction - 0,3%• Contracted Bladder - 0,2%• Renal Abscess - 0,1%• Cytopenia - 0,1%• Osteomyelitis
NTM Infection
• MAC• M. Kansasii• Rapidly Growing – M.Fortuitum, M.Abscessus,
M.Chelonae